Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 6075.75, up 1.29% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.58% on the day, quoting at 24284.95. The Sensex is at 80244.25, up 1.42%. Divis Laboratories Ltd has added around 4.49% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has added around 2.89% in last one month and is currently quoting at 21962.05, up 1.07% on the day. The volume in the stock stood at 1.57 lakh shares today, compared to the daily average of 4.48 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 6100.3, up 1.47% on the day. Divis Laboratories Ltd is up 61.58% in last one year as compared to a 22.1% gain in NIFTY and a 39.6% gain in the Nifty Pharma index.The PE of the stock is 86.7 based on TTM earnings ending September 24.Powered by Capital Market - Live

Total income grew by 22.51% year on year (YoY) to Rs 2,444 crore in the quarter ended 30 September 2024. Profit before tax for the quarter was at Rs 722 crore, up 53.94% from Rs 469 crore reported in the same period a year ago. Total expenses stood at Rs 1,722 crore in second quarter of FY25, up 12.84% on YoY basis. Cost of material consumed was at Rs 976 crore (up 37.27% YoY) and employee benefit expenses stood at Rs 304 crore (up 14.29% YoY) during the period under review. Forex gain for the current quarter amounted to Rs 29 crore as against a gain of Rs 11 crore posted in Q2 FY24. On half yearly basis, the company's net profit climbed 33.52% to Rs 940 crore on 20.86% rise in revenue from operations to Rs 4,456 crore in H1 FY25 over H1 FY24. Forex gain for the six month period amounted to Rs 28 crore as against a gain of Rs 14 crore posted in same period a year ago. Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Shares of Divi's Laboratories declined 0.34% to end at Rs 5,938.15 on Friday, 8 November 2024. Powered by Capital Market - Live

Net profit of Divi's Laboratories rose 46.55% to Rs 510.00 crore in the quarter ended September 2024 as against Rs 348.00 crore during the previous quarter ended September 2023. Sales rose 22.47% to Rs 2338.00 crore in the quarter ended September 2024 as against Rs 1909.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2338.001909.00 22 OPM %30.6225.09 - PBDT821.00564.00 46 PBT722.00469.00 54 NP510.00348.00 47 Powered by Capital Market - Live

Divis Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

Divis Laboratories Ltd dropped for a fifth straight session today. The stock is quoting at Rs 5765.75, down 0.9% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 24547.8. The Sensex is at 80424.19, up 0.25%.Divis Laboratories Ltd has added around 7.25% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 1.88% in last one month and is currently quoting at 22828.2, down 0.33% on the day. The volume in the stock stood at 1.85 lakh shares today, compared to the daily average of 10.54 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 5799.15, down 0.66% on the day. Divis Laboratories Ltd jumped 67.44% in last one year as compared to a 28.37% rally in NIFTY and a 53.74% spurt in the Nifty Pharma index.The PE of the stock is 93.02 based on TTM earnings ending June 24.Powered by Capital Market - Live

The agency has also affirmed the company's short term rating at 'CARE A1+'. CARE Ratings stated that the ratings assigned to bank facilities of Divi's Laboratories continue to derive strength from the extensive experience of promoters and management team in the pharmaceutical industry, the company's established track record in Contract Research and Manufacturing Services (CRAMS) segment with reputed clientele, its strong research and development (R&D) capabilities and favourable industry outlook. Ratings factor in strong credit metrics characterised by sound capital structure, robust debt coverage indicators, and healthy liquidity maintained by the company. However, ratings are tempered by product and customer concentration risk despite reduced in FY24 as against FY23, working capital intensive operations, though funded entirely through internal accruals, exposure to the regulatory risk and forex fluctuation risk considering majority of the revenue being derived from exports. Stabilisation of total operating income (TOI) and attenuation in profitability margins in FY24 is primarily attributed to change in product mix, pricing pressure in generics segment, rise in raw material prices and freight costs. CARE Ratings expects improvement in TOI and margins in FY25 considering launch of new products, broadening of customer base, ease of raw material prices, improving demand, addition of capacity with operationalisation of Kakinada plant in second half of FY25, and increase in overall capacity utilisation. Divi's Laboratories is a pharmaceutical company engaged in generic API, custom synthesis, and nutraceuticals. The company is catering to therapeutic segments such as cardiovascular, anti-inflammatory, anti-cancer, central nervous system drugs among others. Divi's currently has seven manufacturing units (one in Kakinada under construction) and three R&D centres spread across Telangana and Andhra Pradesh. The scrip rose 0.42% to currently trade at Rs 5518.80 on the BSE. Powered by Capital Market - Live

Divis Laboratories has received reaffirmation in credit ratings for bank facilities aggregating Rs 515 crore at CARE AA+; Stable/ CARE A1+ from CARE Ratings. Powered by Capital Market - Live

Divis Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 5161.25, up 0.46% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 24855.65. The Sensex is at 81293.96, up 0.14%. Divis Laboratories Ltd has risen around 5.53% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has risen around 3.38% in last one month and is currently quoting at 23043.4, down 0.37% on the day. The volume in the stock stood at 2.18 lakh shares today, compared to the daily average of 4.9 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5176, up 0.74% on the day. Divis Laboratories Ltd is up 38.14% in last one year as compared to a 24.3% spurt in NIFTY and a 49.95% spurt in the Nifty Pharma index.The PE of the stock is 82.16 based on TTM earnings ending June 24.Powered by Capital Market - Live

Divis Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5151.7, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Divis Laboratories Ltd has risen around 6.71% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 1.87 lakh shares today, compared to the daily average of 4.92 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5159.45, up 0.89% on the day. Divis Laboratories Ltd is up 38.94% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 81.45 based on TTM earnings ending June 24.Powered by Capital Market - Live

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 4884.75, up 3.42% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24728.5. The Sensex is at 80764.15, down 0.05%. Divis Laboratories Ltd has gained around 7.72% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 9.29% in last one month and is currently quoting at 22374.25, up 0.83% on the day. The volume in the stock stood at 10.29 lakh shares today, compared to the daily average of 6.01 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 4881, up 3.44% on the day. Divis Laboratories Ltd is up 33.71% in last one year as compared to a 27.49% jump in NIFTY and a 47.43% jump in the Nifty Pharma index.The PE of the stock is 75.46 based on TTM earnings ending June 24.Powered by Capital Market - Live